Vivimed Labs Ltd.

•

vivimedlabs.comBSE: 532660NSE: VIVIMEDLAB

Market Cap₹ 50 Cr.

Current Price

High / Low₹ 29 / 5

Stock P/E—

Book Value₹ -30

Price to Book-0.20

Dividend Yield0.00 %

ROCE-9.1 %

ROE0.0 %

Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2025 • Pharmaceuticals: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company is almost debt free
Working capital cycle has improved - days down from -166 to -253
Company generates healthy free cash flow

CONS

Net worth is negative - accumulated losses have eroded equity
Company is loss-making at the operating / net level
Company has a low return on equity of -66.8% over last 3 years
Company has a low return on capital employed of -25.5%
Operating cash flow has been negative in recent years
Interest coverage is weak at -9.7x - earnings barely cover interest

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	VIVIMEDLAB	6.07	0.00	50.33	0.00	-147.12	-2527.20	12.00	-53.14	-9.07	-1168.99

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	37	35	34	41	39	29	25	37	26	21	21	16	12
	201	36	40	40	67	40	25	35	28	22	22	27	165
Operating Profit	-164	-0	-6	1	-28	-11	-1	1	-2	-0	-1	-11	-153
OPM %	-443.67%	-0.93%	-17.54%	3.06%	-73.72%	-37.45%	-2.58%	2.90%	-9.64%	-1.31%	-4.66%	-68.29%	-1272.77%
	1	0	2	0	8	0	0	0	4	0	0	0	6
Interest	9	11	12	13	-33	0	0	0	2	1	2	1	1
Depreciation	96	5	5	5	6	4	4	7	6	5	5	5	12
Profit before Tax	-268	-16	-20	-17	7	-15	-5	-6	-5	-5	-7	-17	-147
Tax %	0.77%	-0.00%	-0.00%	3.31%	20.90%	-0.00%	-0.00%	-0.00%	-2.00%	-0.00%	-0.00%	-0.00%	-0.09%
Net Profit	0	0	0	0	5	-15	-5	-6	-6	-5	-7	-17	-147
	-32.08	-1.88	-2.45	-1.94	0.63	-1.84	-0.62	-0.72	-0.68	-0.66	-0.88	-2.00	-17.74

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
	1,346	1,462	1,186	1,315	1,059	861	237	187	149	116	70
	1,123	1,057	985	1,146	1,052	830	245	374	182	129	235
Operating Profit	223	404	201	169	7	32	-8	-187	-33	-13	-165
OPM %	16.57%	27.67%	16.93%	12.84%	0.62%	3.70%	-3.30%	-99.94%	-22.05%	-11.19%	-235.60%
	24	8	24	34	12	10	1	1	10	4	6
Interest	85	68	82	70	61	56	40	36	3	3	4
Depreciation	61	58	56	67	67	55	18	108	20	20	26
Profit before Tax	100	286	86	66	-109	-70	-65	-331	-46	-32	-176
Tax %	16.27%	25.31%	11.22%	13.14%	0.33%	-2.90%	-4.35%	0.64%	0.82%	-0.35%	-0.08%
Net Profit	84	214	76	57	-109	-72	-68	-329	-45	-32	-176
EPS	0.00	0.00	0.00	0.00	-12.77	-8.42	-7.92	-38.46	-5.48	-3.85	—
Dividend Payout %	0.00%	1.51%	4.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	—

COMPOUNDED SALES GROWTH

10 Years:: -22%
5 Years:: -36%
3 Years:: -21%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

STOCK PRICE CAGR

10 Years:: -22%
5 Years:: -23%
3 Years:: -15%
1 Year:: -38%

RETURN ON EQUITY

10 Years:: -19%
5 Years:: -47%
3 Years:: -67%
Last Year:: 0%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	16	16	17	17	17	17	17	17	17	17
Minority Interest	0	0	12	0	0	0	0	0	0	0
	505	718	885	602	493	415	348	23	-22	-52
	955	890	743	820	1,018	697	726	743	845	847
Trade Payables	167	179	202	294	227	34	42	55	44	39
	401	253	527	590	442	127	134	158	67	70
Total Liabilities	2,044	2,055	2,386	2,322	2,196	1,289	1,266	995	951	921
	814	879	1,035	965	1,045	502	520	436	418	408
Capital Work in Progress	94	76	65	122	89	60	40	21	21	17
	3	3	3	3	86	199	199	199	168	168
	491	484	540	564	502	256	241	80	64	59
	0	0	0	0	0	0	0	0	83	74
Cash & Bank	31	55	99	95	50	6	7	4	2	1
	611	558	643	574	423	267	259	256	195	194
Total Assets	2,044	2,055	2,386	2,322	2,196	1,289	1,266	995	951	921

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	154	95	63	437	100	542	28	35	-24	-2
Cash from Investing	-190	-68	-164	-89	-196	404	-16	-5	28	-5
Cash from Financing	41	35	186	-338	72	-1,015	-10	-34	-6	5
	4	25	44	-5	-44	-44	1	-3	-2	-1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	20.94	20.94	20.94	20.94	7.77	7.77	7.77	7.57
	1.64	1.64	1.64	1.64	1.64	1.64	1.64	1.64
DIIs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12
	77.30	77.30	77.30	77.30	90.48	90.48	90.48	90.67

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08

Corporate Insolvency Resolution Process

2026-09-08 - Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process

2026-08-17

Corporate Insolvency Resolution Process

2026-08-17 - Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process

2026-07-31

Clarification - Financial Results

2026-07-31 - The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.

2026-07-22

Updates

2026-07-22 - Vivimed Labs Limited has informed the Exchange regarding 're lodgment'.

2026-07-22

General Updates

2026-07-22 - Vivimed Labs Limited has informed the Exchange about General Updates

2026-07-10

Certificate under SEBI (Depositories and Participants) Regulations, 2018

2026-07-10 - Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

2026-06-30

Trading Window

2026-06-30 - Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

2026-06-25

Reply to Clarification- Financial results

2026-06-25 - The Exchange had sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.

2026-06-17

Disclosure under SEBI Takeover Regulations

2026-06-17 - Vivimed Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

News

Recent coverage and analyst commentary for VIVIMEDLAB

Loading news…

🤖

AI Stock Analyst

Vivimed Labs Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1842.00

36.54

441957.50

0.87

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9326.00

84.64

247576.00

0.32

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4975.00

86.76

189233.01

0.76

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1119.50

24.74

111670.55

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1365.00

32.72

110272.68

0.95

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1970.35

97.37

106460.42

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

DRREDDY

1161.00

30.07

96906.38

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

AUROPHARMA

1675.45

25.97

96401.69

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2096.00

17.34

95842.92

0.86

1416.98

16.01

8276.89

34.28

28.86

29.59

MANKIND

2277.00

46.04

94050.37

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2416.90

37.94

68210.88

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

VIVIMEDLAB

6.07

0.00

50.33

0.00

-147.12

-2527.20

12.00

-53.14

-9.07

-1168.99

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

201

165

Operating Profit

-164

-0

-6

-28

-11

-1

-2

-0

-1

-11

-153

OPM %

-443.67%

-0.93%

-17.54%

3.06%

-73.72%

-37.45%

-2.58%

2.90%

-9.64%

-1.31%

-4.66%

-68.29%

-1272.77%

Interest

-33

Depreciation

Profit before Tax

-268

-16

-20

-17

-15

-5

-6

-5

-7

-17

-147

Tax %

0.77%

-0.00%

3.31%

20.90%

-0.00%

-2.00%

-0.00%

-0.09%

Net Profit

-15

-5

-6

-5

-7

-17

-147

-32.08

-1.88

-2.45

-1.94

0.63

-1.84

-0.62

-0.72

-0.68

-0.66

-0.88

-2.00

-17.74

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

TTM

1,346

1,462

1,186

1,315

1,059

861

237

187

149

116

1,123

1,057

985

1,146

1,052

830

245

374

182

129

235

Operating Profit

223

404

201

169

-8

-187

-33

-13

-165

OPM %

16.57%

27.67%

16.93%

12.84%

0.62%

3.70%

-3.30%

-99.94%

-22.05%

-11.19%

-235.60%

Interest

Depreciation

108

Profit before Tax

100

286

-109

-70

-65

-331

-46

-32

-176

Tax %

16.27%

25.31%

11.22%

13.14%

0.33%

-2.90%

-4.35%

0.64%

0.82%

-0.35%

-0.08%

Net Profit

214

-109

-72

-68

-329

-45

-32

-176

EPS

0.00

-12.77

-8.42

-7.92

-38.46

-5.48

-3.85

—

Dividend Payout %

0.00%

1.51%

4.24%

0.00%

—

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Minority Interest

505

718

885

602

493

415

348

-22

-52

955

890

743

820

1,018

697

726

743

845

847

Trade Payables

167

179

202

294

227

401

253

527

590

442

127

134

158

Total Liabilities

2,044

2,055

2,386

2,322

2,196

1,289

1,266

995

951

921

814

879

1,035

965

1,045

502

520

436

418

408

Capital Work in Progress

122

199

168

491

484

540

564

502

256

241

Cash & Bank

611

558

643

574

423

267

259

256

195

194

Total Assets

2,044

2,055

2,386

2,322

2,196

1,289

1,266

995

951

921

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

154

437

100

542

-24

-2

Cash from Investing

-190

-68

-164

-89

-196

404

-16

-5

Cash from Financing

186

-338

-1,015

-10

-34

-6

-5

-44

-3

-2

-1

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

20.94

7.77

7.57

1.64

DIIs

0.00

0.12

77.30

90.48

90.67

Vivimed Labs Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Vivimed Labs Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI